Alternatives to Trofinetide
Trofinetide is a Biotechnology tool: develops and commercializes treatments for central nervous system disorders, including Rett syndrome. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Trofinetide
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Tortugas Neuroscience51BiotechnologyFramingham, USA$164.0MAdvancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.
- Website
Draig Therapeutics48BiotechnologyNewton, United States$65.0MClinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.
- Website
Lysoway Therapeutics48BiotechnologyCambridge, USA$45.0MDeveloping small-molecule modulators of lysosomal ion channels for neurodegenerative diseases.
- Website
Aelis Farma43BiotechnologyBordeaux, France$54.3MClinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website ACAcurex Biosciences34BiotechnologySan Carlos, USA$1.0M
Biotechnology company developing new medicines for Parkinson's disease and other neurological disorders.
- Website
Supernus Pharmaceuticals60BiotechnologyRockville, United States$17.5MBiopharmaceutical company developing and commercializing CNS disease treatments.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
Showing the 20 closest matches. See the rest on the Trofinetide profile.
Compare Trofinetide head to head
Side by side on what each one does, what it costs, and what real users report.